Brokerages Set GSK plc (LON:GSK) Price Target at GBX 2,034.29

Shares of GSK plc (LON:GSK) have received a consensus recommendation of “Hold” from the seven brokerages that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is GBX 2,034.29.

Several research analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a GBX 1,900 price objective on shares of GSK in a research note on Monday, June 8th. Jefferies Financial Group restated a “buy” rating and issued a GBX 2,500 price objective on shares of GSK in a research note on Thursday, May 28th. Berenberg Bank restated a “hold” rating and set a GBX 2,000 target price on shares of GSK in a research report on Thursday, March 26th. Finally, Citigroup decreased their price target on GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating for the company in a report on Wednesday, May 6th.

Insiders Place Their Bets

In other GSK news, insider Wendy Becker purchased 4,000 shares of the stock in a transaction on Wednesday, April 29th. The shares were bought at an average price of GBX 1,963 per share, for a total transaction of £78,520. Also, insider Jeannie Lee bought 802 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were acquired at an average price of GBX 5,069 per share, for a total transaction of £40,653.38. Over the last quarter, insiders purchased 7,625 shares of company stock worth $21,347,004. 0.20% of the stock is owned by company insiders.

GSK Trading Down 0.2%

LON:GSK opened at GBX 1,901.50 on Friday. The firm has a market cap of £76.17 billion, a P/E ratio of 13.38, a P/E/G ratio of 1.24 and a beta of 0.30. GSK has a one year low of GBX 1,288.61 and a one year high of GBX 2,282. The company has a debt-to-equity ratio of 106.74, a quick ratio of 0.73 and a current ratio of 0.79. The firm has a 50-day simple moving average of GBX 1,930.38 and a 200-day simple moving average of GBX 1,988.22.

GSK (LON:GSK) last announced its earnings results on Wednesday, April 29th. The company reported GBX 46.50 earnings per share (EPS) for the quarter. The business had revenue of GBX 762.90 billion for the quarter. GSK had a return on equity of 35.78% and a net margin of 17.78%. Equities analysts anticipate that GSK will post 175.980975 EPS for the current fiscal year.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.